Complete report is available @ http://www.reportsnreports.com/reports/288100-pharmapoint-migraine-global-drug-forecast-and-market-analysis-to-2023.html . The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

1. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to
2023
Published: May 2014
Single User PDF: US$ 9995
Corporate User PDF: US$ 29985
Order this report by calling
+1 888 391 5441 or Send an email
to sales@reportsandreports.com
with your contact details and
questions if any.
1© ReportsnReports.com / Contact sales@reportsandreports.com

2. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis
to 2023
The migraine market is saturated with generic drugs, and the remaining branded
products already on the market are expected to lose exclusivity during the next
few years, with the exception of Botox for chronic migraine, which is expected to
maintain its leading position in terms of sales. However, reformulations of
mature products as well as new classes of therapies are anticipated to launch
during the forecast period and these will contribute to the market growth.
By 2023, the migraine market will grow to $3.7 billion at a compound annual
growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a
result of higher drug prices and a large migraine population. Some of the new
treatments are expected to target the key unmet needs but opportunities will
remain for further treatment choices especially drugs that will offer an improved
safety and side-effects profile.
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
2© ReportsnReports.com / Contact sales@reportsandreports.com

3. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis
to 2023
Highlights
Key Questions Answered
The migraine market is marked by the presence of a number of unmet needs in
current treatments. What are the main unmet needs in this market? Will the
drugs under development fulfil the unmet needs of the migraine market?
The late-stage migraine pipeline is filled with therapies with diverse formulations
and routes of administration. Which drug will have a significant impact on the
migraine market. Which of these drugs will have the highest CAGR, and why?
The migraine market is currently dominated by generic drugs. How will the
introduction of combinations of device and drugs, and new classes of therapies
change the treatment landscape once reimbursement is not a problem
anymore? How will the drug treatment rates change over the next ten years?
What are the key drivers and barriers to this change?
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
3© ReportsnReports.com / Contact sales@reportsandreports.com

4. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis
to 2023
Key Findings
The main driver of the expansion of the migraine market will be the continuous
use of Botox for chronic migraine. The introduction of reformulations of mature
products as well as new classes of therapies will further increase the market size.
The biggest barrier for the introduction of new therapies will be patent
expirations of the majority of the drugs marketed for migraine, which have
resulted in an increase of generics, and which may negatively impact revenue
from branded drugs that are expected to launch in the forecast period.
The concerns of reducing healthcare costs as part of government austerity
measures, particularly in Europe, which will impede market growth. To ensure
reimbursement companies will have to work closely together with payers and
price their drugs competitively.
Complete report is available
@ http://www.reportsnreports.com/reports/288100-pharmapoint-migraine-
global-drug-forecast-and-market-analysis-to-2023.html .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
4© ReportsnReports.com / Contact sales@reportsandreports.com

5. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis
to 2023
Scope
Overview of migraine, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and treatment guidelines.
Annualized migraine therapeutics market revenue, annual cost of therapy and
treatment usage pattern data from 2012 and forecast for ten years to 2023.
Key topics covered include market characterization, unmet needs, R&D and
clinical trials assessment, late stage clinical trial analysis and implications for the
migraine therapeutics market.
Pipeline analysis: focus on the seven late-stage pipeline drugs discussing
emerging trends as well as overview of earlier phase drugs
.
Buy a copy of this report by publisher name @
http://www.reportsnreports.com/purchase.aspx?name=288100 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
5© ReportsnReports.com / Contact sales@reportsandreports.com

6. PharmaPoint: Migraine - Global Drug Forecast and Market Analysis
to 2023
Reasons to buy
Develop and design your in-licensing and out-licensing strategies through a
review of pipeline products and technologies, and by identifying the companies
with the most robust pipeline. Additionally a list of acquisition targets included
in the pipeline product company list.
Develop business strategies by understanding the trends shaping and driving
the global migraine therapeutics market.
Drive revenues by understanding the key trends, innovative products and
technologies, market segments, and companies likely to impact the global
migraine therapeutics market in future.
Formulate effective sales and marketing strategies by understanding the
competitive landscape and by analysing the performance of various competitors.
Request a Sample of this Report @
http://www.reportsnreports.com/contacts/requestsample.aspx?name=28810
0 .
Order this report by calling +1 888 391 5441 or Send an email to
sales@reportsandreports.com with your contact details and questions if any.
6© ReportsnReports.com / Contact sales@reportsandreports.com